CVS Pharmacy suspends sale of Zantac and CVS brand ranitidine products
Category: #health  By Mateen Dalal  Date: 2019-09-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

CVS Pharmacy suspends sale of Zantac and CVS brand ranitidine products

Lately, Carcinogens have found their way into the generic drug supply of the United States. In 2018, FDA found NDMA, a probable carcinogen for humans, in the widely-used valsartan tablets due to the impurities it had in it. 

A similar case developed recently when CVS Pharmacy, a subsidiary of American health and retail company CVS Health, reportedly announced that it has suspended sales of CVS Health brand and Zantac brand ranitidine products until any further notice over a possible link to cancer.

The pharmaceutical firm took this action out of abundance of caution because of the recent Product Alert issued by the Food and Drug Administration (FDA) about ranitidine products containing low levels of NDMA (nitrosodimethylamine), which is a known animal carcinogen and a probable carcinogen in humans.

Reports cite, Zantac’s official recall has not been issued yet. The FDA has not yet recommended patients to stop the consumption of ranitidine presently.

The FDA is currently working to examine if the low levels of NDMA present in ranitidine products are a risk to patient life. The NDMA levels found by FDA in ranitidine from primary tests hardly exceeds the amount of NDMA present in common foods. However, the company claims, people wishing to return their products can return them for a refund.

The FDA stated that people consuming these medicines shouldn't panic, but it also suggested to switch on any other over-the-counter drug alternative to ranitidine while it would test more samples.

Ranitidine is a H2 Blocker that is consumed to get relief from heartburn. The company would continue selling of other H2 Blockers, which would include Tagamet, Pepcid as well as its respective generic equivalents, cimetidine and famotidine.

Another pharmaceutical firm Novartis had already announced that it would no longer supply Zantac’s generic versions because of the discovery.

Sandoz, a subsidiary of Novartis that prepares generic version of Zantac stated that it has not received any reports regarding adverse events pertaining to the use of the drug as a part of the aforementioned recall. It also stated that patients should approach their respective physician and/or pharmacy for any alternative treatment option.

Sanofi, the company which makes Zantac stated that the FDA reported that N-nitrosodimethylamine (NDMA) levels in ranitidine in its initial tests hardly exceed the amounts present in common foods. However, Sanofi is working closely with FDA and is also conducting its own intensive investigations to make sure that it continues to fulfil the greatest standards of quality and safety.

Source credit: https://www.cbsnews.com/news/zantac-carcinogen-cvs-pharmacy-pulls-zantac-generic-brand-over-possible-link-to-cancer-2019-09-29/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...